A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug Users

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
First received: September 21, 2011
Last updated: May 4, 2016
Last verified: May 2016
This randomized, placebo- and active-controlled, crossover study will evaluate the abuse liability potential of RO4917838 in recreational drug users. In a pre-study (Part 1), subjects will receive a single dose of either diazepam or placebo in an inpatient crossover design, with a wash-out period of at least 10 days between treatments. Subjects who are clearly able to distinguish the positive control from placebo will be enrolled in the main study (Part 2) and will be randomized to single oral doses of RO4917838 (3 dose levels), diazepam and placebo in a double-blind, double-dummy inpatient crossover design. Washout-periods between the 5 treatment periods in Part 2 will be at least 10 days.

Condition Intervention Phase
Healthy Volunteer
Drug: Placebo
Drug: RO4917838
Drug: diazepam
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Pharmacodynamics Study
Masking: Double Blind (Subject, Investigator)
Official Title: Human Abuse Liability Study in Recreational Drug Users to Investigate the Abuse Liability Potential of RO4917838

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Pharmacodynamics: Abuse potential measured by Visual analogue scales (VAS) [ Time Frame: approximately 11 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety: Incidence of adverse events [ Time Frame: approximately 11 months ] [ Designated as safety issue: No ]
  • Pharmacokinetics: plasma concentrations of RO4917838 [ Time Frame: approximately 11 months ] [ Designated as safety issue: No ]
  • Pharmacodynamics: Addiction Research Center Inventory (ARCI) subscales [ Time Frame: approximately 11 months ] [ Designated as safety issue: No ]

Enrollment: 177
Study Start Date: October 2011
Study Completion Date: May 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A Drug: diazepam
Single dose
Placebo Comparator: B Drug: Placebo
Single dose
Experimental: C Drug: RO4917838
Single doses (3 dose levels)


Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male or female volunteers, 18 to 55 years of age inclusive
  • Recreational drug abuse experience (>/= 10 times lifetime abuse of a CNS depressant, >/= 1 abuse of CNS depressant in the previous 3 months
  • Body mass index (BMI) 18 to 30 kg/m2 inclusive
  • Main study (Part 2): Able to differentiate between diazepam and placebo

Exclusion Criteria:

  • History of any significant disease or disorder
  • History or current diagnosis of substance dependence (excluding caffeine and nicotine)
  • Currently seeking or history of participating in treatment for substance-related disorders, including successful completion of such treatment
  • Any confirmed significant allergic reactions against any drug, or multiple allergies in the judgement of the investigator
  • Positive for hepatitis B, hepatitis C or HIV infection
  • Pregnant or lactating women
  • Participation in an investigational drug or device study within the last 30 days prior to Day 1 of the study
  • Confirmed positive drug screening at screening / any Day -1 (allowed positive THC at screening and any Day -1 and positive benzodiazepine at screening only)
  • Positive alcohol breath test at screening / any Day -1
  • Heavy smoker (> 20 cigarettes, > 8 pipefuls or > 8 cigars per day)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01438749

United States, Utah
Salt Lake City, Utah, United States, 84106
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01438749     History of Changes
Other Study ID Numbers: BP25259 
Study First Received: September 21, 2011
Last Updated: May 4, 2016
Health Authority: United States: Food and Drug Administration

ClinicalTrials.gov processed this record on May 25, 2016